TRDA
insider transactionsEntrada Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-77.9K
5.0K buy · 82.9K sell
Net value · 365d
-$1.1M
$29.3K in · $1.2M out
Sentiment · 365d
Net selling
2% buying · 98% selling
Open-market trades · 365d
9
5.0K buy · 82.9K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
19.0K sh
Own New
-
Grant·A
Director, 10% Owner
$0
19.0K sh
Own New
-
Grant·A
Director
$0
19.0K sh
Own New
-
Grant·A
Director
$0
19.0K sh
Own New
-
Grant·A
Director
$0
19.0K sh
Own New
-
Grant·A
Director
$0
19.0K sh
Own New
-
Buy·P
Director
$29.3K
5.0K sh · $5.86
Own New
-
Sell·S
President, Research & Develop. · 10b5-1
$398.8K
25.9K sh · $15.39
Own -11%
-
Exercise·M
Nathan J Dowden KEY
President & COO · 10b5-1
$0
15.0K sh
Own +43%
-
Sell·S
Nathan J Dowden KEY
President & COO · 10b5-1
$230.0K
15.0K sh · $15.33
Own -7%
-
Exercise·M
Nathan J Dowden KEY
President & COO · 10b5-1
$26.1K
15.0K sh · $1.74
Own +8%
-
Sell·S
Chief Financial Officer · 10b5-1
$32.4K
2.5K sh · $12.95
Own -2%
-
Sell·S
Chief Financial Officer · 10b5-1
$148.2K
11.4K sh · $13.02
Own -9%
-
Sell·S
Nathan J Dowden KEY
President & COO · 10b5-1
$155.2K
11.9K sh · $13.05
Own -6%
-
Sell·S
Chief Financial Officer · 10b5-1
$66.2K
5.1K sh · $13.00
Own -4%
-
Sell·S
Nathan J Dowden KEY
President & COO · 10b5-1
$40.6K
3.1K sh · $13.02
Own -1%
-
Sell·S
Chief Financial Officer · 10b5-1
$97.9K
8.0K sh · $12.25
Own -5%
-
Other·F
President, Research & Develop.
$89.1K
7.6K sh · $11.76
Own -3%
-
Other·F
Chief Financial Officer
$67.2K
5.7K sh · $11.76
Own -4%
-
Other·F
Nathan J Dowden KEY
President & COO
$165.0K
14.0K sh · $11.76
Own -6%
-
Other·F
Dipal Doshi KEY
CEO
$225.5K
19.2K sh · $11.76
Own -4%
-
Other·F
President, Research & Develop.
$45.4K
3.9K sh · $11.66
Own -2%
-
Other·F
Chief Financial Officer
$34.3K
2.9K sh · $11.66
Own -2%
-
Other·F
Nathan J Dowden KEY
President & COO
$84.2K
7.2K sh · $11.66
Own -3%
-
Other·F
Dipal Doshi KEY
CEO
$115.1K
9.9K sh · $11.66
Own -2%
-
Grant·A
President, Research & Develop.
$0
83.2K sh
Own New
-
Grant·A
President, Research & Develop.
$0
55.8K sh
Own +28%
-
Grant·A
Chief Financial Officer
$0
66.6K sh
Own New
-
Grant·A
Chief Financial Officer
$0
44.6K sh
Own +41%
-
Grant·A
Nathan J Dowden KEY
President & COO
$0
83.2K sh
Own New
-
Grant·A
Nathan J Dowden KEY
President & COO
$0
55.8K sh
Own +31%
-
Grant·A
Dipal Doshi KEY
CEO
$0
208.0K sh
Own New
-
Grant·A
Dipal Doshi KEY
CEO
$0
139.4K sh
Own +34%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 10, 2026 | Maha Radhakrishnan | Grant A | 19.0K | $0 |
| Jun 10, 2026 | Kush Parmar | Grant A | 19.0K | $0 |
| Jun 10, 2026 | Peter S Kim | Grant A | 19.0K | $0 |
| Jun 10, 2026 | Mary Thistle | Grant A | 19.0K | $0 |
| Jun 10, 2026 | Bernhardt G Zeiher | Grant A | 19.0K | $0 |
| Jun 10, 2026 | Gina Chapman | Grant A | 19.0K | $0 |
| May 20, 2026 | Bernhardt G Zeiher | Buy P | 5.0K | $29.3K |
| May 4, 2026 | Natarajan Sethuraman KEY 10b5-1 | Sell S | 25.9K | $398.8K |
| May 4, 2026 | Nathan J Dowden KEY 10b5-1 | Exercise M | 15.0K | $0 |
| May 4, 2026 | Nathan J Dowden KEY 10b5-1 | Sell S | 15.0K | $230.0K |
| May 4, 2026 | Nathan J Dowden KEY 10b5-1 | Exercise M | 15.0K | $26.1K |
| Apr 1, 2026 | Kory James Wentworth KEY 10b5-1 | Sell S | 2.5K | $32.4K |
| Mar 10, 2026 | Kory James Wentworth KEY 10b5-1 | Sell S | 11.4K | $148.2K |
| Mar 10, 2026 | Nathan J Dowden KEY 10b5-1 | Sell S | 11.9K | $155.2K |
| Mar 9, 2026 | Kory James Wentworth KEY 10b5-1 | Sell S | 5.1K | $66.2K |
| Mar 9, 2026 | Nathan J Dowden KEY 10b5-1 | Sell S | 3.1K | $40.6K |
| Mar 4, 2026 | Kory James Wentworth KEY 10b5-1 | Sell S | 8.0K | $97.9K |
| Mar 3, 2026 | Natarajan Sethuraman KEY | Other F | 7.6K | $89.1K |
| Mar 3, 2026 | Kory James Wentworth KEY | Other F | 5.7K | $67.2K |
| Mar 3, 2026 | Nathan J Dowden KEY | Other F | 14.0K | $165.0K |
| Mar 3, 2026 | Dipal Doshi KEY | Other F | 19.2K | $225.5K |
| Mar 2, 2026 | Natarajan Sethuraman KEY | Other F | 3.9K | $45.4K |
| Mar 2, 2026 | Kory James Wentworth KEY | Other F | 2.9K | $34.3K |
| Mar 2, 2026 | Nathan J Dowden KEY | Other F | 7.2K | $84.2K |
| Mar 2, 2026 | Dipal Doshi KEY | Other F | 9.9K | $115.1K |
| Mar 1, 2026 | Natarajan Sethuraman KEY | Grant A | 83.2K | $0 |
| Mar 1, 2026 | Natarajan Sethuraman KEY | Grant A | 55.8K | $0 |
| Mar 1, 2026 | Kory James Wentworth KEY | Grant A | 66.6K | $0 |
| Mar 1, 2026 | Kory James Wentworth KEY | Grant A | 44.6K | $0 |
| Mar 1, 2026 | Nathan J Dowden KEY | Grant A | 83.2K | $0 |
| Mar 1, 2026 | Nathan J Dowden KEY | Grant A | 55.8K | $0 |
| Mar 1, 2026 | Dipal Doshi KEY | Grant A | 208.0K | $0 |
| Mar 1, 2026 | Dipal Doshi KEY | Grant A | 139.4K | $0 |
About TRDA insider trading
This page tracks insider transactions for Entrada Therapeutics, Inc. (TRDA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.